OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Organon & Co. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexplanon/Implanon NXT | $864.00M | $874.00M | $921.00M | $970.00M | $990.00M | $992.00M | $963.00M | $936.00M | $913.00M | $885.00M | $830.00M | $838.00M | 14.1% | -12.7% |
| Zetia | $366.00M | $344.00M | $342.00M | $329.00M | $317.00M | $318.00M | $317.00M | $309.00M | $297.00M | $317.00M | $322.00M | $336.00M | 6.0% | +15.5% |
| Other | $356.00M | $347.00M | $338.00M | $340.00M | $336.00M | $321.00M | $328.00M | $319.00M | $311.00M | $323.00M | $319.00M | $315.00M | 5.8% | +6.0% |
| Atozet | $327.00M | $333.00M | $324.00M | $335.00M | $365.00M | $419.00M | $473.00M | $519.00M | $520.00M | $523.00M | $519.00M | $504.00M | 5.3% | -10.4% |
| Other Non-Opiod Pain, Bone and Dermatology | $299.00M | $300.00M | $301.00M | $296.00M | $290.00M | $288.00M | $295.00M | $292.00M | $292.00M | $285.00M | $275.00M | $271.00M | 4.9% | +3.1% |
| Hadlima | $278.00M | $249.00M | $228.00M | $204.00M | $181.00M | $159.00M | $142.00M | $122.00M | $90.00M | $69.00M | $44.00M | $25.00M | 4.5% | +53.6% |
| Arcoxia | $269.00M | $263.00M | $265.00M | $255.00M | $253.00M | $258.00M | $270.00M | $262.00M | $257.00M | $261.00M | $257.00M | $263.00M | 4.4% | +6.3% |
| Renflexis | $253.00M | $251.00M | $251.00M | $254.00M | $256.00M | $262.00M | $274.00M | $287.00M | $284.00M | $285.00M | $278.00M | $261.00M | 4.1% | -1.2% |
| Nasonex | $248.00M | $256.00M | $262.00M | $274.00M | $277.00M | $271.00M | $276.00M | $269.00M | $266.00M | $272.00M | $266.00M | $275.00M | 4.0% | -10.5% |
| Follistim AQ | $242.00M | $257.00M | $264.00M | $273.00M | $272.00M | $260.00M | $237.00M | $254.00M | $245.00M | $253.00M | $262.00M | $229.00M | 3.9% | -11.0% |
| Cozaar/Hyzaar | $215.00M | $221.00M | $219.00M | $223.00M | $227.00M | $231.00M | $243.00M | $242.00M | $251.00M | $262.00M | $281.00M | $291.00M | 3.5% | -5.3% |
| Emgality | $208.00M | $196.00M | $174.00M | $163.00M | $141.00M | $129.00M | $107.00M | $69.00M | $40.00M | $10.00M | $0 | – | 3.4% | +47.5% |
| Singulair | $200.00M | $218.00M | $252.00M | $277.00M | $309.00M | $336.00M | $359.00M | $390.00M | $396.00M | $383.00M | $404.00M | $386.00M | 3.3% | -35.3% |
| Other Women's Health | $180.00M | $177.00M | $174.00M | $167.00M | $164.00M | $156.00M | $158.00M | $158.00M | $151.00M | $152.00M | $147.00M | $106.00M | 2.9% | +9.8% |
| Diprospan | $158.00M | $155.00M | $150.00M | $149.00M | $145.00M | $141.00M | $139.00M | $136.00M | $130.00M | $105.00M | $91.00M | $88.00M | 2.6% | +9.0% |
| Dulera | $145.00M | $145.00M | $153.00M | $170.00M | $184.00M | $190.00M | $203.00M | $201.00M | $202.00M | $203.00M | $194.00M | $196.00M | 2.4% | -21.2% |
| Vtama | $133.00M | $129.00M | $128.00M | $101.00M | $67.00M | $36.00M | $12.00M | – | – | – | – | – | 2.2% | +98.5% |
| Fosamax | $130.00M | $139.00M | $143.00M | $146.00M | $144.00M | $145.00M | $151.00M | $149.00M | $152.00M | $161.00M | $159.00M | $158.00M | 2.1% | -9.7% |
| Propecia | $127.00M | $123.00M | $118.00M | $123.00M | $118.00M | $114.00M | $111.00M | $112.00M | $106.00M | $114.00M | $125.00M | $121.00M | 2.1% | +7.6% |
| Clarinex | $116.00M | $120.00M | $123.00M | $120.00M | $122.00M | $123.00M | $127.00M | $128.00M | $129.00M | $133.00M | $136.00M | $132.00M | 1.9% | -4.9% |
| Other Cardiovascular | $114.00M | $123.00M | $126.00M | $131.00M | $127.00M | $125.00M | $133.00M | $126.00M | $138.00M | $142.00M | $139.00M | $138.00M | 1.9% | -10.2% |
| Marvelon/Mercilon | $113.00M | $114.00M | $127.00M | $134.00M | $132.00M | $140.00M | $134.00M | $140.00M | $141.00M | $129.00M | $134.00M | $121.00M | 1.8% | -14.4% |
| Ganirelix Acetate Injection | $98.00M | $99.00M | $101.00M | $103.00M | $107.00M | $107.00M | $109.00M | $104.00M | $103.00M | $110.00M | $110.00M | $115.00M | 1.6% | -8.4% |
| Proscar | $97.00M | $99.00M | $97.00M | $95.00M | $91.00M | $92.00M | $95.00M | $92.00M | $94.00M | $96.00M | $97.00M | $101.00M | 1.6% | +6.6% |
| Nuva Ring | $93.00M | $94.00M | $91.00M | $101.00M | $98.00M | $99.00M | $115.00M | $129.00M | $149.00M | $166.00M | $176.00M | $224.00M | 1.5% | -5.1% |
| Vytorin | $92.00M | $98.00M | $100.00M | $101.00M | $102.00M | $103.00M | $108.00M | $111.00M | $118.00M | $128.00M | $129.00M | $126.00M | 1.5% | -9.8% |
| Brenzys | $78.00M | $86.00M | $80.00M | $73.00M | $77.00M | $67.00M | $77.00M | $91.00M | $77.00M | $78.00M | $73.00M | $68.00M | 1.3% | +1.3% |
| Other | $68.00M | $77.00M | $82.00M | $96.00M | $101.00M | $109.00M | $115.00M | $105.00M | $103.00M | $112.00M | $121.00M | $133.00M | 1.1% | -32.7% |
| Ontruzant | $61.00M | $86.00M | $99.00M | $114.00M | $103.00M | $120.00M | $141.00M | $169.00M | $189.00M | $174.00M | $155.00M | $129.00M | 1.0% | -40.8% |
| Other Biosimilars | $56.00M | $51.00M | $33.00M | $27.00M | $25.00M | – | $28.00M | – | – | – | – | – | 0.9% | +124.0% |
| Other Respiratory | $54.00M | $50.00M | $52.00M | $57.00M | $59.00M | $58.00M | $53.00M | $48.00M | $54.00M | $58.00M | $64.00M | $69.00M | 0.9% | -8.5% |
| Jada | $45.00M | $63.00M | $74.00M | $71.00M | $67.00M | $63.00M | $61.00M | $55.00M | $52.00M | $49.00M | $43.00M | $39.00M | 0.7% | -32.8% |
| Rosuzet | $25.00M | $26.00M | $24.00M | $29.00M | $34.00M | $37.00M | $49.00M | $54.00M | $60.00M | $68.00M | $70.00M | $68.00M | 0.4% | -26.5% |
| Aybintio | – | – | – | – | $22.00M | $25.00M | $28.00M | $31.00M | $36.00M | $41.00M | $43.00M | $44.00M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intl | $4.59B | $4.61B | $4.61B | $4.65B | $4.64B | $4.68B | $4.83B | $4.84B | $4.81B | $4.82B | $4.79B | $4.69B | 75.0% | -1.0% |
| Europe and Canada | $1.67B | $1.65B | $1.62B | $1.63B | $1.65B | $1.69B | $1.76B | $1.76B | $1.71B | $1.72B | $1.67B | $1.65B | 27.2% | +1.0% |
| United States | $1.53B | $1.55B | $1.60B | $1.65B | $1.64B | $1.61B | $1.57B | $1.57B | $1.54B | $1.52B | $1.48B | $1.46B | 25.0% | -6.5% |
| Latin America, Middle East, Russia, and Africa | $1.06B | $1.08B | $1.07B | $1.08B | $1.03B | $1.00B | $1.03B | $1.05B | $1.04B | $1.03B | $965.00M | $917.00M | 17.4% | +2.9% |
| Asia Pacific and Japan | $957.00M | $975.00M | $1.00B | $996.00M | $1.01B | $1.02B | $1.05B | $1.07B | $1.09B | $1.09B | $1.13B | $1.12B | 15.6% | -4.8% |
| China | $823.00M | $819.00M | $829.00M | $840.00M | $833.00M | $845.00M | $847.00M | $837.00M | $827.00M | $845.00M | $864.00M | $857.00M | 13.4% | -1.2% |
| Other | $82.00M | $85.00M | $93.00M | $108.00M | $118.00M | $131.00M | $137.00M | $134.00M | $133.00M | $139.00M | $154.00M | $144.00M | 1.3% | -30.5% |
From the segment and revenue-disaggregation notes of Organon's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.